Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
We see Novo Nordisk and Eli Lilly as overvalued despite assuming that a quarter of US adults with obesity will be on GLP-1 therapies by 2031, leading to a GLP-1 market north of $200 billion in 2031, before generic semaglutide (Wegovy/Ozempic/Rybelsus) launches. Competition rises
Discount -28% 4,95 6,90 In stock Estimated delivery Wednesday 12
Sikiric P, Gojkovic S, Krezic I, Smoday IM, Kalogjera L, Zizek H, Oroz K, Vranes H, Vukovic V, Labidi M, Strbe S, Baketic Oreskovic L, Sever M, Tepes M, Knezevic M, Barisic I, Blagaic V, Vlainic J, Dobric I, Staresinic M, Skrtic A, Jurjevic I, Boban Blagaic A, Seiwerth S
It was observed to have a multifunctional role
The no-DAC version clears in about half an hour
The Centers for Medicare & Medicaid Services (CMS) will negotiate with Eli Lilly in 2026
US$ 28.44
US$ 26.88
US$ 28.98
US$ 28.97
US$ 24.09
